There have been literally thousands of tweets flying out of Stanford’s Med X conference, which isn’t really surprising considering the venue. Here’s just a small smattering.
We live in a real, 3D, tactile world. A 2D screen is actually a frustrating barrier for some people. #MedX
— Paul Grant (@paulgrant) September 5, 2014
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“That is the most tweet-able thing I’ve heard: ‘most technology is great for everyone except for the end user.'” @joshnesbit #MedX #mhealth
— Medic Mobile (@Medic) September 5, 2014
.@DrDanSiegel in #MedX keynote: “Empathy is not just a luxury for physicians; it’s a fundamental part of the system.” pic.twitter.com/4M5H1YkEBh
— Stanford University (@Stanford) September 5, 2014
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
“When we know 91% of people have a texting enabled phone, why shouldn’t we be able to leverage that?” @Veenu_A #MedX
— CCI Voice (@CCIVoice) September 5, 2014
You shouldn’t create a solution that just helps the people who have the latest smartphone. –@dvansickle #MedX
— Stanford Medicine X (@StanfordMedX) September 5, 2014
Vivian Lee from University of Utah tells #MedX that Healthcare Transformation =data+transparency+engagement #Synapse http://t.co/A28GC0gevy
— Synapse (@SynapsePHM) September 5, 2014
Feeling a bit of cognitive dissonance as I look at the beautiful room here and hearing stories of intense health disparities. #MedX
— Ann Becker-Schutte (@DrBeckerSchutte) September 5, 2014
#medx #$10phone + #parallelsimcard runs any mobile app #antenatalcare #childhoodimmunization #diseasesurveillance #drugstocks
— Denise Silber (@health20Paris) September 5, 2014
Safety net orgs are great places to test products: more nimble, and these solutions really work for safety net patients. @Veenu_A #MedX
— CCI Voice (@CCIVoice) September 5, 2014
